Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974515 | 0.77 | SCN9A (0.43) | POLBAPEX1CYP2C19SCN9A | |
| SCHEMBL3540542 | 0.77 | LMNA (0.31) | POLBAPEX1LMNAMAPTHPGD | |
| SCHEMBL9877599 | 0.74 | HSP90AA1 (0.38) | POLBAPEX1MAPTSMN1; SMN2 | |
| SCHEMBL10481252 | 0.74 | HSP90AA1 (0.38) | POLBAPEX1MAPTSMN1; SMN2 | |
| SCHEMBL9423172 | 0.73 | POLB (0.37) | POLBAPEX1CYP2C19LMNAMAPT | |
| SCHEMBL7682549 | 0.72 | GAA (0.41) | POLBAPEX1CYP2C19LMNAMAPT | |
| SCHEMBL9477488 | 0.72 | LMNA (0.40) | POLBAPEX1CYP2C19LMNAMAPT | |
| SCHEMBL30987203 | 0.72 | KEAP1 (0.39) | POLBAPEX1LMNAMAPTHPGD | |
| SCHEMBL977041 | 0.71 | HPGD (0.31) | CYP2C19HPGD | |
| SCHEMBL10916815 | 0.67 | CYP4F2 (0.47) | CYP2C19LMNAMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357695-B2 | Hydrates of 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)-pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide | BASF SE (DE) | 2013-01-22 | — | — | US | disclosed |
| US-7737275-B2 | Method for producing 3-phenyl(thio)uracils and 3-phenyldithiouracils | BASF AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-20100035905-A1 | Hydrates of 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)-pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide | BASF Agro B.V. (CH) | 2010-02-11 | — | — | US | disclosed |
| US-20060293520-A1 | Mehtod for producing 3-phenyl(thio)uracils and 3-phenyldithiouracils | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293520-A1 | Mehtod for producing 3-phenyl(thio)uracils and 3-phenyldithiouracils | HPRT1, TH, METTL3 | POLB 2308/4885APEX1 368/4885CYP2C19 1013/4885 |
| US-20100035905-A1 | Hydrates of 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)-pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide | DHX15, DHX35, BROX | POLB 1622/4885APEX1 1503/4885CYP2C19 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.